As of Apr 20
| +0.11 / +2.25%|
The 2 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +50.00% increase from the last price of 5.00.
The current consensus among 2 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.